1.	Phase III Prospective, Open-Label, Parallel-Group, Randomized, Multicenter Trial Comparing the Efficacy of Surgery, Radiation, and Injection of Murine Cells Producing Herpes Simplex Thymidine Kinase Vector Followed by Intravenous Ganciclovir Against the Efficacy of Surgery and Radiation in the Treatment of Newly Diagnosed, Previously Untreated Glioblastoma Multiforme (Summary Last Modified 06/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GTI-0115, NCI-V96-0990
2.	Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Phase: Phase III Type: Supportive care Status: Completed Age: 16 and over Sponsor: NCI, Other Protocol IDs: 1577.00, FHCRC-1577.00, MSKCC-01127, NCI-H01-0072, NCT00016068
3.	Phase I/II Study of Stereotactic Injection of the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Malignant Glioma (Summary Last Modified 06/97) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: Other Protocol IDs: UCMC-95-3-20-2, NCI-V95-0681
4.	Phase I/II Study of In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir for Recurrent Glioblastoma Multiforme (Summary Last Modified 08/96) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCMC-95-3-20-1, NCI-V95-0682
5.	Phase I/II Study of Intratumoral Gene Therapy: Stereotactic Injection of the Herpes Simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir in Progressive or Recurrent Primary Supratentorial Pediatric Malignant Brain Tumors (Summary Last Modified 02/98) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 3 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: GTI-0106, NCI-V96-0989
6.	Phase I/II Gene Therapy Study of Intratumoral Transduction with the Herpes simplex Thymidine Kinase Gene Followed by Intravenous Ganciclovir in Adults with Recurrent Brain Tumors (Summary Last Modified 08/93) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NINDS Protocol IDs: NINDS-92-N-0246
7.	Phase II Study of In Vivo Gene Therapy With Herpes Simplex Thymidine Kinase in Women With Refractory or Relapsed Ovarian Epithelial Adenocarcinoma, Fallopian Tube Cancer, or Peritoneal Cancer (Summary Last Modified 02/2001) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: HGTRI-0105, NCI-V00-1584, NCT00005025
8.	Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068204, AMC-019, NCT00006264
9.	Phase II Pilot Study of Targeted Oncolytic Virotherapy Comprising Bortezomib, Zidovudine, and Valganciclovir Followed By Effusion Drainage and Bevacizumab in Combination With Chemotherapy Comprising Cyclophosphamide, Doxorubicin, and Etoposide in Patients With Primary Effusion Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0203, NCI-P6330, NCT00217503
10.	Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 98074, P30CA033572, CHNMC-98074, CDR0000564546, NCT00530218
11.	Phase I Study of Genetically Modified CD8+ HIV-Specific T Cells for HIV-Seropositive Patients Undergoing Allogeneic Bone Marrow or Syngeneic T-Cell-Depleted PBSC Transplantation (Summary Last Modified 06/95) Phase: Phase I Type: Treatment Status: Closed Age: 18 to 45 Sponsor: NCI Protocol IDs: FHCRC-696.2, NCI-H94-0411
12.	Phase I Study of Arginine Butyrate and Ganciclovir in Patients With Epstein Barr Virus-Induced Malignancies or Lymphoproliferative Disorders Phase: Phase I Type: Treatment Status: Completed Age: 3 and over Sponsor: Other Protocol IDs: BUMC-3756, BUSM-FDR001532, NCI-V00-1609, NCT00006340
13.	Gene Therapy in Treating Patients With Primary Brain Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000065004, UPCC-3394, NCI-H96-0976, NCT00002824
14.	Phase I Study of Gene Therapy at Optimal Debulking: Treatment of Progressive or Recurrent Pediatric Malignant Supratentorial Brain Tumors with Herpes Simplex Thymidine Kinase Gene Vector Producer Cells Followed by Intravenous Ganciclovir (Summary Last Modified 05/98) Phase: Phase I Type: Treatment Status: Closed Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: GTI-0104, NCI-V96-0988
15.	Phase I Study of Retroviral-Mediated Incorporation of the Herpes Simplex Virus (HSV) Thymidine Kinase Gene and Ganciclovir in Malignant Recurrent Gliomas in Adults (Summary Last Modified 05/1999) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MGH-H97-1122, NCI-H97-1122
16.	Phase I Study of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase/Ganciclovir System for Patients With Refractory or Relapsed Ovarian Adenocarcinoma (Summary Last Modified 03/2000) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: HGTRI-0101, NCI-V97-1177
17.	Phase I Study of Adenovirus RSV-TK and Ganciclovir in Patients With Cutaneous or Subcutaneous Metastatic Malignant Melanoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-98-C-0140C, NCT00005057
18.	Phase I Study of Intrapleurally Administered PA-1-STK Modified Ovarian Carcinoma Vaccine and Ganciclovir in Patients With Stage I, II, or III Malignant Mesothelioma (Summary Last Modified 07/2001) Phase: Phase I Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: LSUMC-3591, NCI-V00-1604, NCT00006216
19.	Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma Phase: Phase I Type: Supportive care, Treatment Status: Completed Age: 1 to 17 Sponsor: NCI, Other Protocol IDs: 1524.00, FHCRC-1524.00, NCI-H00-0065, CDR0000068310, NCT00006480
20.	Randomized Study of Low-Dose Ganciclovir as Early Pre-emptive Therapy in Patients at Risk for Developing Cytomegalovirus-Related Diseases Following Allogeneic Bone Marrow Transplantation (Summary Last Modified 08/93) Phase: No phase specified Type: Supportive care Status: Completed Age: any age Sponsor: Protocol IDs: MSKCC-92118A1, NCI-V93-0251
21.	Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant Phase: No phase specified Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 99061, R01AI058148, P30CA033572, CHNMC-99061, CDR0000600022, NCT00716911
22.	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Temporarily closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 09038, NCI-2010-01932, NCT01199562